Ads
related to: infliximab antibody- Watch Video
What Is RINVOQ®?
Watch A Video To Learn More.
- Real Patient Stories
Learn About Actual RINVOQ®
Patient Experiences. Watch Videos.
- Important Safety Info
Read The Full Safety
& Prescribing Info For RINVOQ®.
- Set Treatment Goals
Talk With Your Doctor About
Setting Goals For Yourself.
- Find A Specialist
Find A Doctor
Near You.
- Talk With Your Doctor
Get Talking Tips To Guide
Conversation With Your Doctor.
- Watch Video
Search results
Results From The WOW.Com Content Network
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease , ulcerative colitis , rheumatoid arthritis , ankylosing spondylitis , psoriasis , psoriatic arthritis , and Behçet's disease . [ 23 ]
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
The incidence of developing these antibodies is highest in patients receiving intermittent therapy with infliximab, and lowest in patient receiving continuous therapy and concomitant immunosuppressive therapy. Some suggest that the presence of these antibodies causes a decrease in efficacy of infliximab and increased risk of infusion reactions.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab, which are effective in rheumatoid arthritis, Crohn's disease and ulcerative colitis by their ability to bind to and inhibit TNF-α. [22] Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help preventing acute rejection of kidney ...
Remicade and Simponi worldwide sales were positively impacted by return of distribution rights in Europe. In neuroscience, Spravato growth of 45.3% continues to be driven by increased physician ...
The anti-TNF monoclonal antibody biologics infliximab, golimumab, certolizumab and adalimumab, and the fusion protein etanercept, which are all currently approved by the FDA for human use, have warnings which state that patients should be evaluated for latent TB infection, and if it is detected, preventive treatment should be initiated prior to ...
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.
Ad
related to: infliximab antibody